JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2016, Vol. 54 ›› Issue (10): 55-59.doi: 10.6040/j.issn.1671-7554.0.2015.1101

Previous Articles     Next Articles

Expressions and significance of Th17 and Th22 cells in peripheral blood of patients with glioma

MAN Qi1, ZHANG An1, ZHANG Yuan2, FAN Mingde1, MA Daoxin3, WANG Chengwei1   

  1. 1. Department of Neurosurgery, Second Hospital of Shandong University, Jinan 250033, Shandong, China;
    2. Department of Emergency, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China;
    3. Department of Hematology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Received:2015-11-12 Online:2016-10-10 Published:2016-10-10

PDF (PC)

351

Abstract: Objective To investigate the expression and significance of Th17 and Th22 cells in the peripheral blood of patients with glioma. Methods A total of 34 patients with glioma and 24 normal controls were enrolled. The percentages of Th17 and Th22 cells in peripheral blood were measured by flow cytometry. Retinoid-related orphan nuclear receptor(RORC)and arylhydrocarbon receptor(AHR)mRNA in peripheral blood mononuclear cells were detected by reverse-transcriptional polymerase chain reaction(RT-PCR). The plasma level of interleukin-22(IL-22)was detected by ELISA. Results There was no difference between patients and healthy controls in circulating Th17 cells(P>0.05), and no difference was found between the high-grade group(WHO Ⅲ-Ⅳ)and low-grade group(WHO Ⅰ-Ⅱ)(P>0.05). The percentage of circulating Th22 cells in glioma was significantly increased compared with that in controls(P<0.05), and the difference between different grade groups was obvious(P<0.05). A positive correlation between Th22 and Th17 cells was observed in glioma(r=0.40, P=0.03), no correlation was found in controls(P>0.05). The difference of RORC and AHR between patients and controls was not significant(P>0.05, P>0.05), 山 东 大 学 学 报 (医 学 版)54卷10期 -满琦,等.脑胶质瘤患者外周血中Th17、Th22细胞的表达及意义 \=-and no difference was found between different grade groups(P>0.05, P>0.05). The serum IL-22 level in patients was significantly increased compared with that in controls(P<0.05). However, there was no difference of serum IL-22 levels between different grade groups(P>0.05). Conclusion There exist abnormal increases of Th22 cells and IL-22 levels in the peripheral blood of glioma, and Th17 and Th22 cells may jointly participate in the pathogenesis and progression of glioma.

Key words: Th17 cells, Th22 cells, Interleukin-22, Glioma

CLC Number: 

  • R739.41
[1] Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011[J]. Neuro Oncol, 2014, 16(Suppl 4): iv1-iv63.
[2] Rolle CE, Sengupta S, Lesniak MS. Challenges in clinical design of immunotherapy trials for malignant glioma[J]. Neurosurg Clin N Am, 2010, 21(1): 201-214.
[3] Galea I, Bernardes-Silva M, Forse PA, et al. An antigen-specific pathway for CD8 T cells across the blood-brain barrier[J]. J Exp Med, 2007, 204(9): 2023-2030.
[4] Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type1 and 2 lineages[J]. Nat Immunol, 2005, 6(11): 1123-1132.
[5] Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells[J]. Cell, 2006, 126(6): 1121-1133.
[6] Trifari S, Kaplan CD, Tran EH, et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells[J]. Nat Immunol, 2009, 10(8): 864-871.
[7] Duhen T, Geiger R, Jarrossay D, et al. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells[J]. Nat Immunol, 2009, 10(8): 857-863.
[8] Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma[J]. Blood, 2008, 112(2): 362-373.
[9] Wang L, Yi T, Kortylewski M, et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway[J]. J Exp Med, 2009, 206(7): 1457-1464.
[10] Wainwright DA, Sengupta S, Han Y, et al. The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma[J]. PLoS One, 2010, 5(10): e15390. doi: 10.1371/journal.pone.0015390.
[11] Hu J, Mao Y, Li M, et al. The profile of Th17 subset in glioma[J]. Int Immunopharmacol, 2011, 11(9): 1173-1179.
[12] Wolk K, Witte E, Witte K, et al. Biology of interleukin-22[J]. Semin Immunopathol, 2010, 32(1):17-31.
[13] Zenewicz LA, Yancopoulos GD, Valenzuela DM, et al. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation[J]. Immunity, 2007, 27(4): 647-659.
[14] Dumoutier L, Louahed J, Renauld JC. Cloning and characterization of IL-10-related T cell-derived inducible factor(IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9[J]. J Immunol, 2000, 164(4):1814-1819.
[15] Zenewicz LA, Flavell RA. Recent advances in IL-22 biology[J]. Int Immunol, 2011, 23(3):159-163.
[16] Witte E, Witte K, Warszawska K, et al. Interleukin-22: a cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection[J]. Cytokine Growth Factor Rev, 2010, 21(5): 365-379.
[17] Xie MH, Aggarwal S, Ho WH, et al. Interleukin(IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R[J]. J Biol Chem, 2000, 275(40): 31335-31339.
[18] Akil H, Abbaci A, Lalloue F, et al. IL22/IL-22R pathway induces cell survival in human glioblastoma cells[J]. PLoS One, 2015, 10(3): e0119872. doi: 10.1371/journal.pone.0119872.
[1] WANG Lin-Lin, SUN Mei-Li, SUN Yu-Ping, ZHANG Nan, LIU Chuan-Yong. Expressions of α-Tubulin and γ-Tubulin in human Glioma and their relation with Survivin [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 103-.
[2] Gang LI,Hao XUE,Wei QIU,Rongrong ZHAO. Research advances in the formation of glioma immunosuppressive microenvironment [J]. Journal of Shandong University (Health Sciences), 2020, 1(8): 67-73.
[3] Qiang WU,Zekun HE,Ju LIU,Xiaomeng CUI,Shuang SUN,Wei SHI. A research on multi-modal MRI analysis based on machine learning for brain glioma [J]. Journal of Shandong University (Health Sciences), 2020, 1(8): 81-87.
[4] Anjing CHEN,Xun ZHANG. The new strategies of targeting SUMOylation in the treatment of glioma [J]. Journal of Shandong University (Health Sciences), 2020, 1(8): 88-94.
[5] Tao JIANG. The application of brain-like intelligence in the frontiers of brain science [J]. Journal of Shandong University (Health Sciences), 2020, 1(8): 10-13.
[6] XU Jixi, CHEN Weijian. Diffuse midline glioma with H3 K27M mutation in the spinal cord: a case report [J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 96-101.
[7] WANG Chaochao, TIAN Hailong, JIANG Huifeng, GUO Wenqiang, WANG Zhigang. Clinical significance of sodium fluorescein-guided resection of high-grade glioma under “yellow fluorescence” mode [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(11): 32-37.
[8] XU Yanjie, CUI Yi, LI Hongxia, SHI Wenqi, LI Fuyan, WANG Jianzhen, ZENG Qingshi. Effect of X-ray on the activity of MMP-2 and Cho/Cr ratio of U87 glioma multicellular spheroid [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(4): 6-10.
[9] DONG Xiaojing, LI Jing, ZHAO Lei, QI Mei, SUN Zeyu, WANG Hong, ZHAO Weiming. Effect of natural killer cells on the production of interleukin-22 and disease process during Chlamydia muridarum lung infection [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(11): 19-23.
[10] TIAN Xinli, JIAO Jun, ZHANG Teng, MA Daoxin, CUI Baoxia. Expression and significance of Th22 and Th17 cells in the peripheral blood of cervical cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(7): 43-47.
[11] BAI Jinxia, BAI Jinyun, SHI Xiuju, XU Hongwei. IL-22 protects mice from acute severe pancreatitis via STAT3 signaling pathway [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(6): 1-6.
[12] ZHANG Rongjun, HAN Bo, GAO Ling, ZHU Mei, DING Guoyu, LIANG Yan. Effects of CD40 knockdown by siRNA on rats with experimental autoimmune myocarditis and IL-22 expression [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(5): 36-40.
[13] YAO Zhong, CHEN Weiliang, XU Yangyang, HE Ying, QU Xun, LI Xingang. Galectin-9 inhibits proliferation and migration of glioma cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(4): 1-5.
[14] ZHU Xiaodong, XIA Tongliang, YAO Qingyu, LI Haoyuan, WANG Benlin, NI Shilei, WANG Jiangang, LI Xingang, SU Wandong. SN-38-loaded electrospun composite nanofiber scaffolds for the treatment of human glioma cells in vitro [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(4): 6-11.
[15] XING Deguang, MA Ermeng, WANG Moulong, SUN Zhongzheng, FAN Mingde, ZANG Yizheng, WANG Chengwei. Experimental research on biological activities of glioma cells inhibited by TRAIL in combination with paclitaxel [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(4): 12-15.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd